CRISPR's $100M+ CASGEVY Run Rate Isn't Enough-CTX310 Is the Real Bull Case

CASGEVY starts the story; CTX310 determines the multiple

CASGEVY may clear $100 million this year, but CTX310 is what decides whether CRISPR becomes more than a one-product story.

CRISPR is not asking the market to underwrite a flat launch. Management says 2026 will be a defining year, but the harder question remains whether in vivo proof can expand the company beyond a commercial companion story tied to one asset.

That is where the bull case begins. CASGEVY still has momentum, and Vertex expects a clear line of sight to over $100 million in total CASGEVY revenue this year. If that remains true, CRISPR has enough operating credibility to earn time while the broader pipeline tries to mature.

The bear case is more direct. If CTX310 disappoints, investors can be expected to keep the valuation tied to a commercial asset whose economics are not fully under CRISPR's control. Commercial traction helps, but it does not automatically move the company into a higher biopharma multiple.

That is why the valuation debate matters now. CRISPR has described the business roughly in thirds: one part Casgevy representing about a third of value, another part Phase 1 assets with promising data, and the rest in deeper pipeline options. The near-term job is to show that the middle third can grow into real franchise value.

CASGEVY shows execution, but it does not settle the valuation

Revenue and access are improving

The CASGEVY funnel matters mainly as proof that CRISPR can execute. The company previously said nearly 300 patients had been referred, with about 165 patients completing cell collection and 39 having received infusions. By year-end, CASGEVY produced $54 million in fourth-quarter 2025 revenue and $116 million for full-year 2025. That is not the profile of a failed launch.

This does more than show demand. It suggests the company can support treatment centers, navigate access, and move patients through a complex care pathway.

Why the multiple stays disciplined

Commercial proof alone, however, does not justify a broader biotech multiple. The issue is not only whether CASGEVY can sell. It is how much of that payoff CRISPR ultimately keeps, given the partnership structure with Vertex.

That leaves the balance sheet as the cleaner near-term advantage. The company entered 2026 with approximately $2 billion in cash, cash equivalents, and marketable securities. That war chest buys time, but it does not remove dependence on CASGEVY for the next several quarters of operating relevance.

So the real question is not whether CASGEVY can continue to support the business. It is whether CRISPR can turn that commercial credibility into a second de-risked asset class. If pipeline updates land, the war chest starts to look like leverage. If they do not, CASGEVY remains funding oxygen rather than an expansion story.

CTX310 is the first real test of CRISPR's in vivo thesis

Why the CTX310 data matter more than a routine Phase 1 readout

The AHA/NEJM CTX310 release matters because it was positioned as a late-breaking presentation and published in a top journal. That usually signals a dataset management sees as especially important.

The biology is also what bulls have been waiting for. Early in vivo results showed ~80% ANGPTL3 reduction, along with meaningful LDL and triglyceride drops. In in vivo editing, that kind of target engagement is an early sign that the platform can create meaningful biological effect, not just theoretical promise.

If that signal holds, CTX310 stops being an interesting mechanism and starts looking like a legitimate franchise candidate.

Platform proof is the bigger prize

The larger bull case is not just one lipid asset. It is whether CTX310 shows that CRISPR's delivery and editing stack can work outside hemoglobinopathies.

If in vivo proof becomes repeatable, other editing and siRNA programs become easier to underwrite. That is how a company moves from asset-by-asset speculation toward a portfolio built on repeatable science.

Where bulls and bears split

The main risk is that biomarker improvement is not the same as a finished development plan. Bears can reasonably argue that lipid reduction, even when impressive, still has to translate into a registrational strategy, endpoints, and trial execution.

That is the next fault line. Bulls need evidence that strong biology can become a plausible regulatory path. Bears will wait until that path is more concrete.

What would strengthen the thesis from here

A more compelling setup would require CRISPR to stack proof points across the portfolio, not rely on CASGEVY alone.

Near-term catalysts to watch

• ASH pediatric exa-cel data: Enrollment is complete in the key pediatric Phase 3 programs, with initial data at ASH serving as the first broader readout beyond the current approved population.
• Broader CTX112 update by year-end: If CRISPR delivers meaningful data across autoimmune disease and oncology, investors can start assessing whether one editing scaffold can support multiple franchises.
• CTX460 clinical start: If initiation proceeds on schedule, the company moves another in vivo program from preclinical promise to live clinical execution.
• Pipeline density by mid-2027: Management has pointed to six programs beyond Casgevy by mid-2027. Delivering on that timeline would help the market underwrite repeatable platform wins rather than isolated hopes.

What would weaken the thesis

• Pediatric exa-cel data fails to clearly extend the market or execution story.
• CTX112 updates remain fragmented across indications.
• CTX460 slips or underwhelms relative to the preclinical pitch.
• The pipeline calendar keeps expanding without enough clinical evidence to back it.

CASGEVY is strong enough to keep the company relevant. CTX310 and the surrounding pipeline have to prove CRISPR can stay valuable beyond it.